Prof. Heerspink: DAPA-CKD and Use of Dapagliflozin

September 3, 2020

A podcast featuring the presenter of DAPA-CKD discussing results of the trial and how they inform use of dapagliflozin in patients with chronic kidney disease with and without type 2 diabetes.

In this special edition episode of the Endocrine Outlook, you will hear from Professor Hiddo Heerspink, PhD, on dapagliflozin as a treatment in patients with chronic kidney disease.


Heerspink recently presented results of the DAPA-CKD trial at the European Society of Cardiology Congress 2020. The trial examined the effects of dapagliflozin (Farxiga) in patients with chronic kidney disease with and without type 2 diabetes. This episode further explores the study and how its results inform the use of dapagliflozin in patients with and without type 2 diabetes.